Assessing generalisability through the use of disease registers: findings from a diabetes cohort study. Issue 1 (27th August 2011)

• Record Type: Journal Article
• Authors: David, Michael; Ware, Robert; Donald, Maria; Alati, Rosa
• Is Part Of: BMJ open. Volume 1:Issue 1(2011)
• Publication Date: 2011-08-27
• Subjects: Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2011-000078
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: Knowledge of a study population's similarity to the target population allows researchers to assess the generalisability of their results. Often generalisability is assessed through a comparison of baseline characteristics between individuals who did and did not respond to an invitation to participate in a study. In this prospective population-based cohort, we broadened this assessment by comparing participants with all individuals from a chronic disease register who satisfied the study eligibility criteria but for a number of reasons, such as the absence of consent to be approached for research purposes, did not participate. Methods: Data are from the Living with Diabetes Study, a population-based cohort of individuals diagnosed with diabetes mellitus, which commenced in Queensland, Australia in 2008. Individuals were sampled from a federally-funded diabetes register. We compared the characteristics of 3951 study participants with 10 488 non-participants (individuals who were invited to participate but declined) and with 129 900 non-study individuals on the register who did not participate in the study. Results: Study participants were more likely than non-study registrants to be male, aged 50–69, have type 2 diabetes non-insulin requiring, be recently registered and be non-indigenous Australians. Study participants were more likely than non-participants to be aged 50–69, have type 1 diabetes and be non-indigenous Australians. Conclusions: The interpretation of a study's generalisability can alter depending on which non-participating group is compared with participants. When assessing generalisability, participants should be compared with the largest possible group of non-participating individuals. When sampling from a disease register, researchers should be wary of the influence of research consent procedures on the register's coverage.